OCALA, FLA. (VINnews) — Scientists at the AdventHealth facility in Ocala, Florida, announced that they have discovered a treatment for coronavirus which has produced an almost 100 percent success rate on those it was tested on.
Patients at the facility were treated with a combination of drugs which already exist which doctors call ICAM, an acronym for the four active components of the treatment. The treatment includes Immunosupport drugs (Vitamin C and Zinc), Corticosteroids to combat inflammation, Anticoagulents such as Enoxaparin can be used to prevent and to treat blood clots in more serious cases and Macrolides to help combat infection.
AdventHealth Ocala officials confirmed the highly successful results from the latest drug therapy developed by Dr. Carlette Norwood-Williams, Director of Pharmacy at AdventHealth Ocala. “The ICAM protocol has the potential to trigger the reopening of the country,” Dr. Norwood-Williams told the International Business Times. “We will know the next step after our out-patient study,” she added.
Norwood-Williams developed the treatment due to the severe shortages and high cost of Remedesvir, the only known drug capable of treating COVID-19. She explained that the ICAM protocol was developed based on consideration of how patients’ inflammatory response reacted to the medications. In the majority of deaths associated with the virus, COVID-19 is no longer active in the body. Death occurs from the body’s inflammation response to the infection.” So ICAM was conceived and based on this consideration, Norwood-Williams noting, “It provides protection in the body until the virus runs out of gas.”
Norwood-Williams explained that ICAM works by reinforcing the immune system and also giving protection to the lungs from inflammation. “We had no need for mechanical ventilation and the patients all survived the discharge regardless of age and regardless of past medical history,” Norwood-Williams stated.
From April, they have witnessed a 96.4 percent survival rate in the case of coronavirus patients admitted at the AdventHealth Ocala. Norwood-Williams stated in the AdventHealth system’s news account that “For 76 days our patients had zero transfers to the intensive care unit, zero mechanical ventilator placement and zero death with ICAM and ICAM similar regimens.”
“What we found out was that ICAM works as a strategy for super defense for the body,” Norwood-Williams added. “It doesn’t kill coronavirus, but it doesn’t need to. Viruses are self-limiting anyway. They have a very short life cycle. What kills people are the consequences of coronavirus in multiple ways,” she added.
The researchers are starting a clinical trial for the drug therapy in order to publish their findings and share treatment with physicians around the world.
Donate to DOJLife.com